A novel single-chain antibody redirects adenovirus to IL13Rα2-expressing brain tumors

Scientific Reports

Volumn 5, Issue , 2015, Pages

  Kim, Julius W ^a,b   Young, Jacob S ^a   Solomaha, Elena ^a   Kanojia, Deepak ^a   Lesniak, Maciej S ^a,b   Balyasnikova, Irina V ^a,b  

^a UNIVERSITY OF CHICAGO   (United States)

^b NORTHWESTERN UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GREEN FLUORESCENT PROTEIN; IL13RA1 PROTEIN, HUMAN; INTERLEUKIN 13 RECEPTOR ALPHA1; INTERLEUKIN 13 RECEPTOR ALPHA2; PROTEIN BINDING; SINGLE CHAIN FRAGMENT VARIABLE ANTIBODY;

ADENOVIRIDAE; ANIMAL; ANTAGONISTS AND INHIBITORS; BINDING COMPETITION; BRAIN NEOPLASMS; CHO CELL LINE; CONFOCAL MICROSCOPY; CRICETULUS; DRUG SCREENING; GENETICS; GLIOMA; HAMSTER; HEK293 CELL LINE; HUMAN; IMMUNOLOGY; KINETICS; MALE; METABOLISM; NUDE MOUSE; SURFACE PLASMON RESONANCE; TUMOR CELL CULTURE; TUMOR CELL LINE;

ADENOVIRIDAE; ANIMALS; BINDING, COMPETITIVE; BRAIN NEOPLASMS; CELL LINE, TUMOR; CHO CELLS; CRICETINAE; CRICETULUS; GLIOMA; GREEN FLUORESCENT PROTEINS; HEK293 CELLS; HUMANS; INTERLEUKIN-13 RECEPTOR ALPHA1 SUBUNIT; INTERLEUKIN-13 RECEPTOR ALPHA2 SUBUNIT; KINETICS; MALE; MICE, NUDE; MICROSCOPY, CONFOCAL; PROTEIN BINDING; SINGLE-CHAIN ANTIBODIES; SURFACE PLASMON RESONANCE; TUMOR CELLS, CULTURED; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84949908750     PISSN: None     EISSN: 20452322     Source Type: Journal    
DOI: 10.1038/srep18133     Document Type: Article

References (46)

1. Stupp, R. et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med 352, 987-996, doi: 10.1056/NEJMoa043330 (2005).
2. Zheng, S. et al. Fiber-knob modifications enhance adenoviral tropism and gene transfer in malignant glioma. The journal of gene medicine 9, 151-160, doi: 10.1002/jgm.1008 (2007).
3. Van Houdt, W. J. et al. The human survivin promoter: a novel transcriptional targeting strategy for treatment of glioma. J Neurosurg 104, 583-592, doi: 10.3171/jns.2006.104.4.583 (2006).
4. Ulasov, I. V. et al. Comparative evaluation of survivin, midkine and CXCR4 promoters for transcriptional targeting of glioma gene therapy. Cancer biology & therapy 6, 679-685 (2007).
5. Ulasov, I. V. et al. Survivin-driven and fiber-modified oncolytic adenovirus exhibits potent antitumor activity in established intracranial glioma. Human gene therapy 18, 589-602, doi: 10.1089/hum.2007.002 (2007).
6. Ulasov, I. V. et al. Combination of adenoviral virotherapy and temozolomide chemotherapy eradicates malignant glioma through autophagic and apoptotic cell death in vivo. British journal of cancer 100, 1154-1164, doi: 10.1038/sj.bjc.6604969 (2009).
7. Chakravarti, A. et al. Quantitatively determined survivin expression levels are of prognostic value in human gliomas. Journal of clinical oncology: official journal of the American Society of Clinical Oncology 20, 1063-1068 (2002).
8. Uematsu, M. et al. Prognostic significance of the immunohistochemical index of survivin in glioma: a comparative study with the MIB-1 index. Journal of neuro-oncology 72, 231-238, doi: 10.1007/s11060-004-2353-3 (2005).
9. Choi, B. D. et al. Systemic administration of a bispecific antibody targeting EGFRvIII successfully treats intracerebral glioma. Proceedings of the National Academy of Sciences of the United States of America 110, 270-275, doi: 10.1073/pnas.1219817110 (2013).
10. Kong, S. et al. Suppression of human glioma xenografts with second-generation IL13R-specific chimeric antigen receptor-modified T cells. Clinical cancer research: an official journal of the American Association for Cancer Research 18, 5949-5960, doi: 10.1158/1078-0432.CCR-12-0319 (2012).
11. Krebs, S. et al. T cells redirected to interleukin-13Ralpha2 with interleukin-13 mutein-chimeric antigen receptors have anti-glioma activity but also recognize interleukin-13Ralpha1. Cytotherapy 16, 1121-1131, doi: 10.1016/j.jcyt.2014.02.012 (2014).
12. Riccione, K. et al. Generation of CAR T Cells for Adoptive Therapy in the Context of Glioblastoma Standard of Care. Journal of visualized experiments: JoVE, doi: 10.3791/52397 (2015).
13. Zitron, I. M. et al. Targeting and killing of glioblastoma with activated T cells armed with bispecific antibodies. BMC cancer 13, 83, doi: 10.1186/1471-2407-13-83 (2013).
14. Debinski, W., Obiri, N. I., Powers, S. K., Pastan, I. & Puri, R. K. Human glioma cells overexpress receptors for interleukin 13 and are extremely sensitive to a novel chimeric protein composed of interleukin 13 and pseudomonas exotoxin. Clinical cancer research: an official journal of the American Association for Cancer Research 1, 1253-1258 (1995).
15. Joshi, B. H., Plautz, G. E. & Puri, R. K. Interleukin-13 receptor alpha chain: a novel tumor-associated transmembrane protein in primary explants of human malignant gliomas. Cancer Res 60, 1168-1172 (2000).
16. Jarboe, J. S., Johnson, K. R., Choi, Y., Lonser, R. R. & Park, J. K. Expression of interleukin-13 receptor alpha2 in glioblastoma multiforme: implications for targeted therapies. Cancer Res 67, 7983-7986, doi: 10.1158/0008-5472.CAN-07-1493 (2007).
17. Brown, C. E. et al. Glioma IL13Rα 2 Is Associated with Mesenchymal Signature Gene Expression and Poor Patient Prognosis. PLoS One 8, e77769, doi: 10.1371/journal.pone.0077769 (2013).
18. Ulasov, I. V., Tyler, M. A., Han, Y., Glasgow, J. N. & Lesniak, M. S. Novel recombinant adenoviral vector that targets the interleukin-13 receptor alpha2 chain permits effective gene transfer to malignant glioma. Human gene therapy 18, 118-129, doi: 10.1089/hum.2006.146 (2007).
19. Balyasnikova, I. V. et al. Characterization and immunotherapeutic implications for a novel antibody targeting interleukin (IL)-13 receptor alpha2. The Journal of biological chemistry 287, 30215-30227, doi: 10.1074/jbc.M112.370015 (2012).
20. Bartolomé, R. A. et al. IL13 Receptor α 2 Signaling Requires a Scaffold Protein, FAM120A, to Activate the FAK and PI3K Pathways in Colon Cancer Metastasis. Cancer Res 75, 2434-2444, doi: 10.1158/0008-5472.can-14-3650 (2015).
21. Hedley, S. J. et al. An adenovirus vector with a chimeric fiber incorporating stabilized single chain antibody achieves targeted gene delivery. Gene Ther 13, 88-94, doi: 10.1038/sj.gt.3302603 (2006).
22. Krasnykh, V., Belousova, N., Korokhov, N., Mikheeva, G. & Curiel, D. T. Genetic targeting of an adenovirus vector via replacement of the fiber protein with the phage T4 fibritin. Journal of virology 75, 4176-4183, doi: 10.1128/JVI.75.9.4176-4183.2001 (2001).
23. Kaliberov, S. A. et al. Adenoviral targeting using genetically incorporated camelid single variable domains. Laboratory investigation; a journal of technical methods and pathology 94, 893-905, doi: 10.1038/labinvest.2014.82 (2014).
24. Kipriyanov, S. M., Kupriyanova, O. A., Little, M. & Moldenhauer, G. Rapid detection of recombinant antibody fragments directed against cell-surface antigens by flow cytometry. Journal of immunological methods 196, 51-62 (1996).
25. Toleikis, L., Broders, O. & Dubel, S. Cloning single-chain antibody fragments (scFv) from hybridoma cells. Methods in molecular medicine 94, 447-458 (2004).
26. Curiel, D. T. Strategies to adapt adenoviral vectors for targeted delivery. Annals of the New York Academy of Sciences 886, 158-171 (1999).
27. Kim, J. W. et al. A Genetically Modified Adenoviral Vector with a Phage Display Derived Peptide Incorporated into Fiber Fibritin Chimera Prolongs Survival in Experimental Glioma. Human gene therapy, doi: 10.1089/hum.2015.008 (2015).
28. Bergelson, J. M. et al. Isolation of a common receptor for Coxsackie B viruses and adenoviruses 2 and 5. Science (New York, N.Y.) 275, 1320-1323 (1997).
29. Tomko, R. P., Xu, R. & Philipson, L. HCAR and MCAR: the human and mouse cellular receptors for subgroup C adenoviruses and group B coxsackieviruses. Proceedings of the National Academy of Sciences of the United States of America 94, 3352-3356 (1997).
30. Fuxe, J. et al. Expression of the coxsackie and adenovirus receptor in human astrocytic tumors and xenografts. International journal of cancer. Journal international du cancer 103, 723-729, doi: 10.1002/ijc.10891 (2003).
31. Asaoka, K., Tada, M., Sawamura, Y., Ikeda, J. & Abe, H. Dependence of efficient adenoviral gene delivery in malignant glioma cells on the expression levels of the Coxsackievirus and adenovirus receptor. J Neurosurg 92, 1002-1008, doi: 10.3171/jns.2000.92.6.1002 (2000).
32. Allen, C. et al. Interleukin-13 displaying retargeted oncolytic measles virus strains have significant activity against gliomas with improved specificity. Mol Ther 16, 1556-1564, doi: 10.1038/mt.2008.152 (2008).
33. Kioi, M., Seetharam, S. & Puri, R. K. Targeting IL-13Ralpha2-positive cancer with a novel recombinant immunotoxin composed of a single-chain antibody and mutated Pseudomonas exotoxin. Mol Cancer Ther 7, 1579-1587, doi: 10.1158/1535-7163.mct-07-2131 (2008).
34. Kunwar, S. et al. Phase III randomized trial of CED of IL13-PE38QQR vs Gliadel wafers for recurrent glioblastoma. Neuro-oncology 12, 871-881, doi: 10.1093/neuonc/nop054 (2010).
35. Auffinger, B., Spencer, D., Pytel, P., Ahmed, A. U. & Lesniak, M. S. The role of glioma stem cells in chemotherapy resistance and glioblastoma multiforme recurrence. Expert review of neurotherapeutics, 1-12, doi: 10.1586/14737175.2015.1051968 (2015).
36. Brown, C. E. et al. Stem-like tumor-initiating cells isolated from IL13Ralpha2 expressing gliomas are targeted and killed by IL13-zetakine-redirected T Cells. Clinical cancer research: an official journal of the American Association for Cancer Research 18, 2199-2209, doi: 10.1158/1078-0432.ccr-11-1669 (2012).
37. Ogden, A. T. et al. Identification of A2B5+ CD133-tumor-initiating cells in adult human gliomas. Neurosurgery 62, 505-514; discussion 514-505, doi: 10.1227/01.neu.0000316019.28421.95 (2008).
38. Jarboe, J. S., Johnson, K. R., Choi, Y., Lonser, R. R. & Park, J. K. Expression of Interleukin-13 Receptor α 2 in Glioblastoma Multiforme: Implications for Targeted Therapies. Cancer Research 67, 7983-7986, doi: 10.1158/0008-5472.can-07-1493 (2007).
39. Gan, H. K., Kaye, A. H. & Luwor, R. B. The EGFRvIII variant in glioblastoma multiforme. Journal of clinical neuroscience: official journal of the Neurosurgical Society of Australasia 16, 748-754, doi: 10.1016/j.jocn.2008.12.005 (2009).
40. Beatty, G. L. et al. Mesothelin-specific chimeric antigen receptor mRNA-engineered T cells induce anti-tumor activity in solid malignancies. Cancer immunology research 2, 112-120, doi: 10.1158/2326-6066.CIR-13-0170 (2014).
41. Kane, J. R. et al. Sui generis: gene therapy and delivery systems for the treatment of glioblastoma. Neuro-oncology 17 Suppl 2, ii24-ii36, doi: 10.1093/neuonc/nou355 (2015).
42. Patel, M. A., Kim, J. E., Ruzevick, J., Li, G. & Lim, M. The future of glioblastoma therapy: synergism of standard of care and immunotherapy. Cancers 6, 1953-1985, doi: 10.3390/cancers6041953 (2014).
43. Yan, K. et al. Glioma cancer stem cells secrete Gremlin1 to promote their maintenance within the tumor hierarchy. Genes & development 28, 1085-1100, doi: 10.1101/gad.235515.113 (2014).
44. Balyasnikova, I. V. et al. Cloning and characterization of a single-chain fragment of monoclonal antibody to ACE suitable for lung endothelial targeting. Microvascular research 80, 355-364, doi: 10.1016/j.mvr.2010.09.007 (2010).
45. Wilkinson-Ryan, I. et al. Incorporation of porcine adenovirus 4 fiber protein enhances infectivity of adenovirus vector on dendritic cells: implications for immune-mediated cancer therapy. PLoS One 10, e0125851, doi: 10.1371/journal.pone.0125851 (2015).
46. Livak, K. J. & Schmittgen, T. D. Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. Methods 25, 402-408, doi: 10.1006/meth.2001.1262 (2001).